← Leaderboards
Ramesh Ramanathan
University Of Pittsburgh At Pittsburgh
$303,574
Attributed
$303,574
Total exposure
14
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$303,574 · 14
By mechanism
M01$303,574 · 14
Top collaborators
No co-investigators on record.
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- Joel S Greenberger$22,565,586
- Jian Yu$10,881,915
- Andrew F. Stewart$27,613,128
- Robert H. Getzenberg$8,211,645
- Surinder Kumar Batra$34,830,369
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationClinical Trial Phase INeoplasm /Cancer ChemotherapyPancreas NeoplasmsNeoplasm /Cancer ImmunotherapyPatient Oriented ResearchDrug Screening /EvaluationDrug Administration Rate /DurationDosageNeoplasm /Cancer VaccineAntitumor AntibodyBiliary Tract NeoplasmCamptothecinColorectal NeoplasmsGadoliniumGemcitabineGene ExpressionImmunomodulatorsMetalloporphyrinsMetastasisMonoclonal AntibodyMucins
Grant awards (28)
A PHASE I TRIAL OF WEEKLY 17-ALLYAMINO-17 DEMETHOXYGELDANAMYCIN (17AAG)$88,605
M01 · FY2005 · RR
PH1 (17-DMAG) IN PTS W/ADV SOLID TUMORS$44,969
M01 · FY2005 · RR
PH1 PHARM PS341 IN PTS W/ADV MALIGN VARYING DEGREES RENAL DYSF CTEP$29,646
M01 · FY2005 · RR
PH1 PHARMACO EPOTHILONE B ANALOGUE BMS-247550 ADV MALIGN LIVER$3,331
M01 · FY2005 · RR
RNDM PH2 NON COMPARE OF SB-715992 WKLY OR EVRY 3 WKS IN METASTATIC COL CANCER$2,998
M01 · FY2005 · RR
PH1 PHARMCO STDY ST1571 PTS W/ADV MALIG LEVELS LIVER DYSFUNCTION$667
M01 · FY2005 · RR
A PH1B STDY MUCI PULSED DENDRITIC CELL VACCINE IN PTS W/RESECTED PANCREATIC$337
M01 · FY2005 · RR
A Phase I Trial of Weekly 17AAG$64,866
M01 · FY2004 · RR
PH2 Trial Rebeccamycin in Hepatobiliary Cancer$27,982
M01 · FY2004 · RR
PH1 Pharmco Stdy ST1571 Pts w/Adv Malig. Liver Disorder$25,692
M01 · FY2004 · RR
PH I Pharmacokinetics Stdy ST1571 in Advanced Malignancy$7,631
M01 · FY2004 · RR
PHI Study Wkly Docetaxel in Combo w/Capecitabine$3,816
M01 · FY2004 · RR
9 NITRO CAMPTOTHECIN IN ADVANCED COLORECTAL CANCER$0
M01 · FY2002 · RR
DOSE ESCALATION TRIAL OF 100AA SYNTHETIC MUCIN PEPTIDE PANCREATIC CANCER$0
M01 · FY2002 · RR
DOSE ESCALATION TRIAL OF 100AA SYNTHETIC MUCIN PEPTIDE PANCREATIC CANCER$0
M01 · FY2002 · RR
GADOLINIUM TEXAPHYRIN RADIOTHERAPY IN BILIARY/PANCREAS C$0
M01 · FY2002 · RR
GADOLINIUM TEXAPHYRIN RADIOTHERAPY IN BILIARY/PANCREAS C$0
M01 · FY2002 · RR
HERCEPTIN, GEMCITABINE FOR METASTATIC PANCREATIC CANCER$0
M01 · FY2002 · RR
HERCEPTIN, GEMCITABINE FOR METASTATIC PANCREATIC CANCER$0
M01 · FY2002 · RR
9 NITRO CAMPTOTHECIN IN ADVANCED COLORECTAL CANCER$0
M01 · FY2002 · RR
DOSE ESCALATION TRIAL OF 100AA SYNTHETIC MUCIN PEPTIDE PANCREATIC CANCER$0
M01 · FY2001 · RR
9 NITRO CAMPTOTHECIN IN ADVANCED COLORECTAL CANCER$0
M01 · FY2001 · RR
HERCEPTIN, GEMCITABINE FOR METASTATIC PANCREATIC CANCER$0
M01 · FY2001 · RR
GADOLINIUM TEXAPHYRIN RADIOTHERAPY IN BILIARY/PANCREAS C$0
M01 · FY2001 · RR
DOSE ESCALATION TRIAL OF 100AA SYNTHETIC MUCIN PEPTIDE PANCREATIC CANCER$3,034
M01 · FY2000 · RR
9 NITRO CAMPTOTHECIN IN ADVANCED COLORECTAL CANCER$0
M01 · FY2000 · RR
HERCEPTIN, GEMCITABINE FOR METASTATIC PANCREATIC CANCER$0
M01 · FY2000 · RR
GADOLINIUM TEXAPHYRIN RADIOTHERAPY IN BILIARY/PANCREAS C$0
M01 · FY2000 · RR